Biotech Business - November 28, 2025
FDA grants Medivir’s MIV-711 Orphan Drug Designation
Medivir's selective cathepsin K inhibitor, MIV-711, has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Osteogenesis Imperfecta (OI).
Financing - November 27, 2025
Gosta Labs completes EUR 7.5 million oversubscribed seed round
The Helsinki-based healthtech company, founded by the ex-Kaiku Health founders, has closed a seed round to scale its AI operating system for complex medical specialties.
Clinical Trials - November 26, 2025
First subject dosed in One-carbon Therapeutics study
The first subject has been dosed in the company's ODIN Phase 1/2 clinical trial evaluating TH9619, a first-in-class MTHFD1/2 inhibitor.
Careers article - November 26, 2025
Elekta reduces its workforce by 450 employees
As a consequence of a zero-based review of the organization, Elekta will reduce its global workforce by approximately 450 employees with a major effect on managerial positions.
Collaboration - November 26, 2025
FluoGuide and ZEISS sign collaboration agreement
The objective of the collaboration is to develop FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
Biotech Business - November 24, 2025
Alvotech receives European approval of a biosimilar to Prolia and Xgeva
“This milestone reflects not only the dedication and expertise of our teams, but also the strong partnerships we have built to bring affordable medicines to patients across Europe,” says Robert Wessman, Chairman and Chief Executive Officer of Alvotech.
